Skip to main content
SpringerLink
Log in
Book cover

Tumor Angiogenesis pp 1–22Cite as

Cytotoxics and Anti-Angiogenics: Metronomic Therapies

  • Living reference work entry
  • First Online:

  • 171 Accesses

Abstract

A vascular bed brings nutrients and oxygen to malignant tumors and is a prerequisite for their growth and spread throughout the body. There are many compounds that can inhibit angiogenesis in cancer. Twenty years ago, the anti-angiogenic effects of conventional cytotoxic drugs have been described, leading to a plethora of preclinical and clinical evaluations of virtually all known chemotherapeuticals. The anti-angiogenic effects are observed at much lower doses than conventionally given and the concept of anti-angiogenic chemotherapy or metronomic chemotherapy evolved, i.e., the administration of low doses of cytotoxic agents over a prolonged period instead of maximum tolerated doses in repeated cycles in conventional chemotherapeutic regimens. Here, we will focus on the principles of the anti-angiogenic effects of chemotherapeuticals, the combination of anti-angiogenic compounds with conventional chemotherapeutic agents and metronomic chemotherapy, including a compilation of the clinical effects in patients with cancer.

This is a preview of subscription content, log in via an institution.

References

  • Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10(4):301–306. doi:10.3816/CBC.2010.n.039

    Article  CAS  PubMed  Google Scholar 

  • Bandyopadhyay A, Das M, Kundu SK (2014) Metastatic primary duodenal adeno-carcinoma responding to metronomic oral cyclophosphamide chemotherapy. Indian J Palliat Care 20(3):239–242. doi:10.4103/0973-1075.138402

    Article  PubMed  PubMed Central  Google Scholar 

  • Banys-Paluchowski M, Schütz F, Ruckhäberle E, Krawczyk N, Fehm T (2016) Metronomic chemotherapy for metastatic breast cancer – a systematic review of the literature. Geburtshilfe Frauenheilkd 76(5):525–534. doi:10.1055/s-0042-105871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G Jr, Dzik C (2015) Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Med Oncol 32(1):443. doi:10.1007/s12032-014-0443-4

  • Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11):1843–1849

    CAS  PubMed  Google Scholar 

  • Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D’Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer 14:184. doi:10.1186/1471-2407-14-184

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15):4342–4346

    CAS  PubMed  Google Scholar 

  • Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG task force. Cancer Treat Rev 43:19–26. doi:10.1016/j.ctrv.2015.11.009

    Article  CAS  PubMed  Google Scholar 

  • Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23):6938–6943

    CAS  PubMed  Google Scholar 

  • Bojko P, Schimmel G, Bosse D, Abenhardt W (2012) Metronomic oral cyclophosphamide in patients with advanced solid tumors. Onkologie 35(1–2):35–38. doi:10.1159/000336144

    Article  CAS  PubMed  Google Scholar 

  • Borjan B, Steiner N, Karbon S, Kern J, Francesch A, Hermann M, Willenbacher W, Gunsilius E, Untergasser G (2015) The aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo. BMC Cancer 15:738. doi:10.1186/s12885-015-1729-4

    Article  PubMed  PubMed Central  Google Scholar 

  • Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623–3628. doi:10.1200/JCO.2005.04.5773

    Article  CAS  PubMed  Google Scholar 

  • Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, Serra C, Sama C, Golfieri R, Gramenzi A, Cucchetti A, Pinna AD, Trevisani F, Biasco G (2013) Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 18(12):1256–1257. doi:10.1634/theoncologist.2013-0093

    Article  PubMed  PubMed Central  Google Scholar 

  • Bronstad A, Berg A, Reed RK (2004) Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 287(2):H963–H968. doi:10.1152/ajpheart.01052.2003

    Article  CAS  PubMed  Google Scholar 

  • Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886

    CAS  PubMed  Google Scholar 

  • Brugieres L, Pacquement H, Le Deley MC, Leverger G, Lutz P, Paillard C, Baruchel A, Frappaz D, Nelken B, Lamant L, Patte C (2009) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 27(30):5056–5061. doi:10.1200/JCO.2008.20.1764

    Article  CAS  PubMed  Google Scholar 

  • Caro M, Font A, Comas S, Viciano M, Remon J, Celiz P, Robles J, Musulen E, Sendros MJ, Mesalles E, Jimenez JA, Boix J, Arellano A, Fernandez-Llamazares J (2016) Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma. Clin Transl Oncol. doi:10.1007/s12094-016-1488-y

    Google Scholar 

  • Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P (2014) Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014:769790. doi:10.1155/2014/769790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cesca M, Bizzaro F, Zucchetti M, Giavazzi R (2013) Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 3:259. doi:10.3389/fonc.2013.00259

    Article  PubMed  PubMed Central  Google Scholar 

  • Chung FT, Lee KY, Fang YF, Shieh MH, Lin SM, Yu CT, Lo YL, Lin TY, Kuo CH, Feng PH, Ni YL, Kuo HP (2011) Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. Chemotherapy 57(2):147–155. doi:10.1159/000321037

    Article  CAS  PubMed  Google Scholar 

  • Colleoni M, Gray KP, Gelber S, Lang I, Thurlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A (2016) Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International breast cancer study Group trial 22-00. J Clin Oncol. doi:10.1200/jco.2015.65.6595

    Google Scholar 

  • Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P (2011) Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 12(2):112–118

    Article  CAS  PubMed  Google Scholar 

  • Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G (2010) Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 9(9):685–693

    Article  PubMed  Google Scholar 

  • De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S (2016) Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med 14(1):113. doi:10.1186/s12967-016-0857-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S (2015) On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori 101(1):30–35. doi:10.5301/tj.5000207

    Article  PubMed  Google Scholar 

  • de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S (2015) Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol 171(5):720–725. doi:10.1111/bjh.13653

    Article  PubMed  CAS  Google Scholar 

  • Deenen MJ, Meulendijks D, Boot H, Legdeur MC, Beijnen JH, Schellens JH, Cats A (2015) Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemother Pharmacol 76(6):1285–1295. doi:10.1007/s00280-015-2872-y

    Article  CAS  PubMed  Google Scholar 

  • Demirci U, Dizdar O, Cetindag MF, Altinova S, Ozsavran A, Dede DS, Kizilirmak N, Eraslan FA, Yalcin B, Cinkir HY (2015) Radiotherapy concurrent with weekly gemcitabine after transurethral tumor resection in muscle invasive bladder cancer. J Cancer Res Ther 11(4):704–707. doi:10.4103/0973-1482.147381

    Article  CAS  PubMed  Google Scholar 

  • Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S, Patil VM (2016) Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer 5(2):63–66. doi:10.4103/2278-330x.181629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13(13):3942–3950. doi:10.1158/1078-0432.CCR-07-0278

    Article  CAS  PubMed  Google Scholar 

  • Dudley AC (2012) Tumor endothelial cells. Cold Spring Harb Perspect Med 2(3):a006536. doi:10.1101/cshperspect.a006536

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Eelen G, de Zeeuw P, Simons M, Carmeliet P (2015) Endothelial cell metabolism in normal and diseased vasculature. Circ Res 116(7):1231–1244. doi:10.1161/CIRCRESAHA.116.302855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • El-Husseiny K, Motawei H, Ali MS (2016) Continuous low-dose oral cyclophosphamide and methotrexate as maintenance therapy in patients with advanced ovarian carcinoma after complete clinical response to platinum and paclitaxel chemotherapy. Int Journal Gynecol Cancer 26(3):437–442. doi:10.1097/igc.0000000000000647

    Article  Google Scholar 

  • Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, Andre N, Barlesi F (2016) A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer 16(1):278. doi:10.1186/s12885-016-2308-z

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Farhat F, Kattan JG, Ghosn M (2016) Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Cancer Chemother Pharmacol 77(5):1069–1077. doi:10.1007/s00280-016-3027-5

    Article  CAS  PubMed  Google Scholar 

  • Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, Ranganathan S, Marina N (2013) A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children's oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer 60(3):409–414. doi:10.1002/pbc.24328

    Article  CAS  PubMed  Google Scholar 

  • Ferrara N, Adamis AP (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15(6):385–403. doi:10.1038/nrd.2015.17

    Article  CAS  PubMed  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. doi:10.1056/NEJM197111182852108

    Article  CAS  PubMed  Google Scholar 

  • Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286. doi:10.1038/nrd2115

    Article  CAS  PubMed  Google Scholar 

  • Gangjee A, Pavana RK, Ihnat MA, Thorpe JE, Disch BC, Bastian A, Bailey-Downs LC, Hamel E, Bai R (2014) Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential. ACS Med Chem Lett 5(5):480–484. doi:10.1021/ml4004793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol 26(1):76–82. doi:10.1200/jco.2007.12.1939

    Article  CAS  PubMed  Google Scholar 

  • Gebbia V, Boussen H, Valerio MR (2012) Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res 32(2):529–536

    CAS  PubMed  Google Scholar 

  • Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V (2015) Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol 95(1):46–61. doi:10.1016/j.critrevonc.2015.01.008

    Article  PubMed  Google Scholar 

  • Gorn M, Habermann CR, Anige M, Thom I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E (2008) A pilot study of docetaxel and trofosfamide as second-line ‘metronomic’ chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 31(4):185–189. doi:10.1159/000118626

    Article  PubMed  CAS  Google Scholar 

  • Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, Benevento F, Bolondi L (2015) Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis 47(6):518–522. doi:10.1016/j.dld.2015.03.010

    Article  CAS  PubMed  Google Scholar 

  • Greiner J, Kufer R, Reske SN, Martin V, Dohner H, Ringhoffer M (2010) Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. Case Rep Med 2010:395720. doi:10.1155/2010/395720

    Article  PubMed  PubMed Central  Google Scholar 

  • Gunsilius E, Gierlich T, Mross K, Gastl G, Unger C (2001) Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Investig 19(8):808–811

    Article  CAS  Google Scholar 

  • Gupta PK, Lal P, Bajpai R, Goel A, Yadav R, Verma M, Kumar S (2016) Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer. South Asian J Cancer 5(2):80–84. doi:10.4103/2278-330x.181647

    Article  PubMed  PubMed Central  Google Scholar 

  • Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045–1047. doi:10.1172/JCI9872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H (2016a) Heterogeneity of tumor endothelial cells and drug delivery. Adv Drug Deliv Rev 99(Pt B):140–147. doi:10.1016/j.addr.2015.11.008

    Article  CAS  PubMed  Google Scholar 

  • Hida K, Maishi N, Torii C, Hida Y (2016b) Tumor angiogenesis-characteristics of tumor endothelial cells. Int J Clin Oncol 21(2):206–212. doi:10.1007/s10147-016-0957-1

    Article  CAS  PubMed  Google Scholar 

  • Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL (2010) Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53(1):126–131. doi:10.1016/j.jhep.2010.01.035

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi:10.1056/NEJMoa032691

    Article  CAS  PubMed  Google Scholar 

  • Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J (2013) A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3(12):1364–1377. doi:10.1158/2159-8290.CD-13-0183

    Article  CAS  PubMed  Google Scholar 

  • Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31(17):2205–2218. doi:10.1200/JCO.2012.46.3653

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jellvert A, Lissbrant IF, Edgren M, Ovferholm E, Braide K, Olvenmark AM, Kindblom J, Albertsson P, Lennernas B (2011) Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med 2(4):579–584. doi:10.3892/etm.2011.272

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kapoor A, Beniwal SK, Kalwar A, Singhal MK, Nirban RK, Kumar HS (2016) Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: a prospective pilot study. South Asian J Cancer 5(2):70–72. doi:10.4103/2278-330x.181644

    Article  PubMed  PubMed Central  Google Scholar 

  • Kareva I, Waxman DJ, Lakka Klement G (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358(2):100–106. doi:10.1016/j.canlet.2014.12.039

    Article  CAS  PubMed  Google Scholar 

  • Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V (2015) Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic oncology research Group (HORG). Cancer Chemother Pharmacol 75(4):821–827. doi:10.1007/s00280-015-2707-x

    Article  CAS  PubMed  Google Scholar 

  • Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK (2013) A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer 109(7):1725–1734. doi:10.1038/bjc.2013.553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kerschbaumer J, Schmidt FA, Grams AE, Nowosielski M, Pinggera D, Brawanski KR, Petr O, Thome C, Tuettenberg J, Seiz M, Freyschlag CF (2015) Dual anti-angiogenic chemotherapy with temozolomide and Celecoxib in selected patients with malignant Glioma not eligible for standard treatment. Anticancer Res 35(9):4955–4960

    CAS  PubMed  Google Scholar 

  • Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS (2013) Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha. Int J Cancer 132(1):29–41. doi:10.1002/ijc.27666

    Article  CAS  PubMed  Google Scholar 

  • Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anti-Cancer Drugs 23(2):230–238. doi:10.1097/CAD.0b013e32834d7a1c

    Article  CAS  PubMed  Google Scholar 

  • Kucukoner M, Isikdogan A, Yaman S, Gumusay O, Unal O, Ulas A, Elkiran ET, Kaplan MA, Ozdemir N, Inal A, Urakci Z, Buyukberber S (2012) Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev 13(8):3973–3976

    Article  PubMed  Google Scholar 

  • Kumar A, Sharma A, Mohanti BK, Thakar A, Shukla NK, Thulkar SP, Sikka K, Bhasker S, Singh CA, Vishnubhatla S (2015) A phase 2 randomized study to compare short course palliative radiotherapy with short course concurrent palliative chemotherapy plus radiotherapy in advanced and unresectable head and neck cancer. Radiother Oncol 117(1):145–151. doi:10.1016/j.radonc.2015.07.026

    Article  PubMed  Google Scholar 

  • Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, Gravis G, Cappiello M, Provansal M, Extra JM, Bertucci F, Viens P, Goncalves A (2016) METRO1: a phase I study of metronomic chemotherapy in adults with advanced refractory solid tumors. Anticancer Res 36(1):293–299

    CAS  PubMed  Google Scholar 

  • Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugieres L (2010) Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol Off 28(25):3987–3993. doi:10.1200/JCO.2010.28.5999

    Article  CAS  Google Scholar 

  • Liang W, Ni Y, Chen F (2016) Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions. Oncotarget 7(13):15444–15459. doi:10.18632/oncotarget.6999

    Article  PubMed  PubMed Central  Google Scholar 

  • Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49(16):3387–3395. doi:10.1016/j.ejca.2013.06.038

    Article  CAS  PubMed  Google Scholar 

  • Lin J-S, Cheng C-Y, Liu C-J (2015) Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma. J Dent Sci 10(4):408–413. doi:10.1016/j.jds.2015.03.004

    Article  Google Scholar 

  • Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH (2007) Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 60(3):351–356. doi:10.1007/s00280-006-0377-4

    Article  CAS  PubMed  Google Scholar 

  • Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2):452–459. doi:10.1182/blood-2005-11-4570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583–592. doi:10.1038/nrc1893

    Article  CAS  PubMed  Google Scholar 

  • Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A (2011) Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer 47(4):515–519. doi:10.1016/j.ejca.2010.11.025

    Article  CAS  PubMed  Google Scholar 

  • Miura N, Tanji N, Yanagihara Y, Noda T, Asai S, Nishimura K, Shirato A, Miyauchi Y, Kikugawa T, Yokoyama M (2015) Low-dose docetaxel combined with dexamethasone is feasible for patients with castration-resistant prostate cancer. Chemotherapy 61(1):23–31. doi:10.1159/000440942

    Article  CAS  PubMed  Google Scholar 

  • Montiel M, Urso L, de la Blanca EP, Marsigliante S, Jimenez E (2009) Cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity. Cell Physiol Biochem 23(4–6):441–448. doi:10.1159/000218191

    Article  CAS  PubMed  Google Scholar 

  • Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, Kaspar M, Trachsel E, Kosmehl H, Bani MR, Neri D, Giavazzi R (2012) Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 72(7):1814–1824. doi:10.1158/0008-5472.CAN-11-1919

    Article  CAS  PubMed  Google Scholar 

  • Mutlu H, Musri FY, Artac M, Kargi A, Ozdogan M, Bozcuk H (2015) Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. J Cancer Res Ther 11(2):287–290. doi:10.4103/0973-1482.154008

    Article  CAS  PubMed  Google Scholar 

  • Nakajima M, Kato H, Sakai M, Sano A, Miyazaki T, Sohda M, Inose T, Tanaka N, Suzuki S, Masuda N, Fukuchi M, Kuwano H (2015) Planned esophagectomy after neoadjuvant hyperthermo-chemoradiotherapy using weekly low-dose Docetaxel and hyperthermia for advanced esophageal carcinomas. Hepato-Gastroenterology 62(140):887–891

    PubMed  Google Scholar 

  • Nakano M, Shoji S, Higure T, Kawakami M, Tomonaga T, Terachi T, Uchida T (2016) Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. Mol Clin Oncol 4(6):942–946. doi:10.3892/mco.2016.830

    PubMed  PubMed Central  Google Scholar 

  • Nasr KE, Osman MA, Elkady MS, Ellithy MA (2015) Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med 3(19):284. doi:10.3978/j.issn.2305-5839.2015.11.14

    PubMed  PubMed Central  Google Scholar 

  • Noronha V, Sahu A, Patil VM, Joshi A, Ramaswamy A, Chandrasekharan A, Kadam N, Prabhash K (2016) Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian J Cancer 5(2):67–69. doi:10.4103/2278-330x.181643

    Article  PubMed  PubMed Central  Google Scholar 

  • Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, Ohmura H, Shinohara N, Nonomura K, Shindoh M, Hida K (2012) Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 180(3):1294–1307. doi:10.1016/j.ajpath.2011.11.035

    Article  CAS  PubMed  Google Scholar 

  • Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology 15(2):242–250. doi:10.1093/neuonc/nos295

    Article  CAS  PubMed  Google Scholar 

  • Otsuka H, Fujii T, Toh U, Iwakuma N, Takahashi R, Mishima M, Takenaka M, Kakuma T, Tanaka M, Shirouzu K (2015) Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast Cancer 22(4):335–342. doi:10.1007/s12282-013-0483-1

    Article  PubMed  Google Scholar 

  • Ozdemir N, Aksoy S, Sendur MA, Akinci MB, Yazici O, Budakoglu B, Abali H, Oksuzoglu B, Zengin N (2013) Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. J BUON 18(4):831–837

    CAS  PubMed  Google Scholar 

  • Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1):40–50. doi:10.1016/j.critrevonc.2011.04.009

    Article  PubMed  Google Scholar 

  • Polverini PJ, Novak RF (1986) Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem Biophys Res Commun 140(3):901–907

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE 2nd, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS (2011) Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neuro-Oncol 103(2):371–379. doi:10.1007/s11060-010-0403-6

    Article  CAS  Google Scholar 

  • Reissig A, Walther M (2013) Old wine in new pipes? Treatment of advanced non-small cell lung cancer with trofosfamide. Onkologie 36(7–8):409–413. doi:10.1159/000353544

    CAS  PubMed  Google Scholar 

  • Revannasiddaiah S, Joshi SC, Pandey KC, Rastogi M, Sharma M, Gupta M (2015) The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma. Ann Transl Med 3(20):305. doi:10.3978/j.issn.2305-5839.2015.11.25

    PubMed  PubMed Central  Google Scholar 

  • Roberto M, Romiti A, Onesti CE, D'Antonio C, Milano A, Falcone R, Barucca V, Palombi L, Righini R, Marchetti P (2016) A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs 27(2):106–111. doi:10.1097/cad.0000000000000308

    Article  CAS  PubMed  Google Scholar 

  • Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(4):636–642. doi:10.1002/pbc.24794

    Article  PubMed  Google Scholar 

  • Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P (2013) Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 72(1):13–33. doi:10.1007/s00280-013-2125-x

    Article  CAS  PubMed  Google Scholar 

  • Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D’Antonio C, Durante V, Milano A, Falcone R, Di Rocco R, Righini R, Marchetti P (2015) Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol 32(3):54. doi:10.1007/s12032-015-0496-z

    Article  PubMed  CAS  Google Scholar 

  • Rueda A, Garcia-Sanz R, Pastor M, Salar A, Labrador J, Quero-Blanco C, Casanova M, Provencio M (2015) A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. Acta Oncol 54(6):933–938. doi:10.3109/0284186x.2015.1007212

    Article  CAS  PubMed  Google Scholar 

  • Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y, Mitsumori M, Hiraoka M (2011) Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 34(2):115–119. doi:10.1097/COC.0b013e3181c4c7a8

    CAS  PubMed  Google Scholar 

  • Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT (2016) Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat. doi:10.1007/s10549-016-3851-7

    PubMed  PubMed Central  Google Scholar 

  • Steiner N, Nachbaur D, Konig P, Willenbacher W, Gunsilius E (2015a) Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone. Anticancer Res 35(4):2165–2168

    CAS  PubMed  Google Scholar 

  • Steiner N, Ribatti D, Willenbacher W, Jöhrer K, Kern J, Marinaccio C, Aracil M, García-Fernández LF, Gastl G, Untergasser G, Gunsilius E (2015b) Marine compounds inhibit growth of multiple myeloma in vitro and in vivo. Oncotarget 6(10):8200–8209

    Article  PubMed  PubMed Central  Google Scholar 

  • Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi:10.1200/jco.2010.33.9101

    Article  CAS  PubMed  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  • Sutiman N, Zhang Z, Tan EH, Ang MK, Tan SW, Toh CK, Ng QS, Chowbay B, Lim WT (2016) Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules. PLoS One 11(5):e0154316. doi:10.1371/journal.pone.0154316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier oncology Group trial, HEM01-21. Oncologist 12(1):99–106. doi:10.1634/theoncologist.12-1-99

    Article  CAS  PubMed  Google Scholar 

  • Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, Investigators RS (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508. doi:10.1016/S1470-2045(15)70127-0

    Article  CAS  PubMed  Google Scholar 

  • Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, Boucher Y, Powell SN (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23(9):1951–1961. doi:10.1200/JCO.2005.08.119

    Article  CAS  PubMed  Google Scholar 

  • Takeshita J, Masago K, Fujita S, Hata A, Kaji R, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Tomii K, Shintani T, Takayama K, Kokubo M, Katakami N (2014) Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: a case series of 20 patients. Mol Clin Oncol 2(3):454–460. doi:10.3892/mco.2014.249

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tan EH, Tan DS, Li WY, Haaland B, Ang MK, Chau NM, Toh CK, Tan IB, Koh TS, Thng CH, Chowbay B, Hui KM, Lim WT, Ng QS (2015) Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer 88(3):289–296. doi:10.1016/j.lungcan.2015.04.001

    Article  PubMed  Google Scholar 

  • Uysal M, Ozdogan M, Kargi A, Gunduz S, Sezgin Goksu S, Murat Tatli A, Arslan D, Mutlu H, Senol Coskun H, Bozcuk H (2014) Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer. J BUON 19(4):980–984

    PubMed  Google Scholar 

  • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506. doi:10.1200/JCO.2012.42.8201

    Article  PubMed  CAS  Google Scholar 

  • Wang J, McGuire TR, Britton HC, Schwarz JK, Loberiza FR Jr, Meza JL, Talmadge JE (2015) Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clin Exp Metastasis 32(2):111–124. doi:10.1007/s10585-015-9696-3

    Article  CAS  PubMed  Google Scholar 

  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147. doi:10.1038/nm988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Woo HY, Youn JM, Bae SH, Jang JW, Cha JH, Kim HL, Chun HJ, Choi BG, Choi JY, Yoon SK (2012) Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. Korean J Hepatol 18(1):32–40. doi:10.3350/kjhep.2012.18.1.32

    Article  PubMed  PubMed Central  Google Scholar 

  • Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y (2015) A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 15:601. doi:10.1186/s12885-015-1606-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yang S, Li S, Yu H, Li S, Liu W, Liu X, Ma H (2016) Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer. Curr Oncol 23(3):e248–e252. doi:10.3747/co.23.3010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zapletalova D, Andre N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, Kutnikova L, Valik D, Sterba J (2012) Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 82(5):249–260. doi:10.1159/000336483

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Wei W, Liu J, Yang H, Jiang Y, Tang W, Li Q, Liao X (2016) Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. Onco Targets Ther 9:3443–3450. doi:10.2147/ott.s104431

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhong DT, Wu RP, Wang XL, Huang XB, Lin MX, Lan YQ, Chen Q (2015) Combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. Pathol Oncol Res 21(4):867–873. doi:10.1007/s12253-015-9903-1

    Article  PubMed  Google Scholar 

  • Zhou F, Ling C, Guo L, Wei W, Li L, Shi H, Hou J (2014) Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leuk Lymphoma. doi:10.3109/10428194.2014.887711

    Google Scholar 

  • Zhu YP, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Shi GH, Lin GW, Ye DW (2014) Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. Kaohsiung J Med Sci 30(2):82–85. doi:10.1016/j.kjms.2013.07.004

    Article  PubMed  Google Scholar 

  • Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, Amoroso D, Galli C, Andreuccetti M, Falcone A, Zagonel V (2013) Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 33(8):3487–3494

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & Oncology, Internal Medicine V, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria

    Andreas Pircher, Normann Steiner & Eberhard Gunsilius

Authors
  1. Andreas Pircher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Normann Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eberhard Gunsilius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Pircher .

Editor information

Editors and Affiliations

  1. Tumor Biology Center, Freiburg, Baden-Württemberg, Germany

    Dieter Marmé

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Pircher, A., Steiner, N., Gunsilius, E. (2017). Cytotoxics and Anti-Angiogenics: Metronomic Therapies. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-31215-6_12-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31215-6_12-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31215-6

  • Online ISBN: 978-3-319-31215-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation